NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December

NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) is set to engage with investors at a series of prominent conferences in December 2025. This late-stage biopharmaceutical firm, based in Naarden, Netherlands, focuses on developing innovative oral, non-statin medications for patients at risk of cardiovascular disease (CVD) characterized by elevated low-density lipoprotein cholesterol (LDL-C). Currently, many existing therapies fail to adequately address the needs of these patients, creating a significant market opportunity for NewAmsterdam’s treatments.

The company management will attend three investor conferences. On December 2nd, Ian Somaiya, Chief Financial Officer, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference in Coral Gables, Florida, slated for 3:50 p.m. ET. The following day, December 3rd, Dr. Michael Davidson, Chief Executive Officer, and Ian Somaiya will join another fireside chat at Citi’s 2025 Global Healthcare Conference in Miami at 3:15 p.m. ET. Finally, on December 4th, both Dr. Davidson and Somaiya are scheduled to speak at the Piper Sandler 37th Annual Healthcare Conference in New York at 8:00 a.m. ET.

Investors interested in the discussions can access live webcasts on NewAmsterdam’s investor relations webpage, with replays made available post-event.

NewAmsterdam is making strides in the cardiovascular domain with its lead investigational drug, obicetrapib, a once-daily CETP inhibitor. This drug is currently undergoing multiple phase 3 trials to assess its efficacy in lowering LDL-C levels, either as a standalone therapy or in combination with ezetimibe, catering specifically to patients for whom current treatment options are insufficient. The company’s mission is to fulfill a critical unmet medical need in the treatment of metabolic diseases.

As NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) prepares to participate in several high-profile investor conferences in December 2025, investors might consider evaluating the implications of these engagements on the company’s market position and stock performance. NewAmsterdam is focused on developing innovative therapies for patients with elevated low-density lipoprotein cholesterol (LDL-C), a critical area within the biopharmaceutical sector, particularly given the growing prevalence of cardiovascular diseases (CVD).

The participation of key executives, including CEO Michael Davidson and CFO Ian Somaiya, in fireside chats at conferences hosted by Evercore, Citi, and Piper Sandler signals proactive efforts to enhance visibility and engage with investors. These appearances can often lead to increased interest from institutional investors and analysts, which may positively impact the company’s stock price as the conference dates approach.

Investors should closely monitor announcements regarding NewAmsterdam’s Phase 3 clinical trials for obicetrapib, a novel CETP inhibitor designed to lower LDL-C. Success in these trials can position NewAmsterdam favorably in a market longing for effective and well-tolerated therapies, potentially translating to significant revenue opportunities. Additionally, the presence of management at these conferences offers a platform for delivering updates on trial progress and corporate strategy, thereby establishing transparency and building investor confidence.

Moreover, NewAmsterdam’s focus on solutions for patients who do not respond well to existing therapies indicates a strategic move to capture unmet needs in the marketplace, which is a strong growth driver. Investors might consider utilizing the live webcasts and archived replays of the conferences to glean deeper insights into management's vision and operational updates.

In summary, NewAmsterdam Pharma's upcoming participation in these investor conferences presents a strategic opportunity for stakeholders to engage with the company. Investors should prepare to capitalize on the potential for positive momentum surrounding both the management discussions and ongoing clinical developments.